Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor
Year: 2006
Type: article
Source: Molecular Cancer Therapeutics
Authors: Daniel H. Albert, Paul Tapang, Terrance J. Magoc, Lori J. Pease, David R. Reuter, Ru-Qi Wei, Junling Li, Jun Guo, Peter F. Bousquet, Nayereh S. Ghoreishi-Haack, Baole Wang, Gail T. Bukofzer, Yi-Chun Wang, Jason A. Stavropoulos, Kresna Hartandi, Amanda L. Niquette, Nirupama Soni, Eric F. Johnson, J. Owen McCall, Jennifer J. Bouska, Yanping Luo, Cherrie K. Donawho, Yujia Dai, Patrick A. Marcotte, Keith B. Glaser, Michael R. Michaelides, Steven K. Davidsen
Institution: Abbott (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: ABT-869, VEGF receptor inhibition, PDGF receptor inhibition, KDR, CSF1R, FLT3, antiproliferative activity, apoptosis, angiogenesis inhibition, corneal neovascularization, uterine edema, tumor xenografts, breast cancer, glioma, leukemia, squamous cell carcinoma, fibrosarcoma, small cell lung cancer, colon cancer, combination therapy, pharmacokinetics, plasma protein binding
Open Access status: closed
OpenAlex ID: W922724308
